
ACAD Stock Forecast & Price Target
ACAD Analyst Ratings
Bulls say
Acadia Pharmaceuticals is supported by two durable commercial franchises, with Nuplazid generating $202.2M in 3Q26 and Daybue delivering a notable $140.1M beat, lifting full-year revenue guidance to $1.265B-$1.295B while the company ended 3Q26 with $976M in cash. Its positive outlook is further reinforced by Daybue’s accelerating Stix uptake, which has already reached more than 50% of U.S. patients and still appears to have room to expand, plus early European launch activity that could add another growth leg. Beyond the current base business, management’s pipeline offers meaningful optionality through remlifanserin and ACP-211, and even with higher-risk readouts ahead, the valuation appears to understate the resilience and scale of the existing revenue stream.
Bears say
Acadia Pharmaceuticals is viewed negatively because its valuation depends heavily on two commercial products, yet both face meaningful execution risk from slower-than-expected uptake, worsening reimbursement, and potential regulatory or clinical delays. Nuplazid could see flattening growth in Parkinson’s disease psychosis, while Daybue’s launch in Rett syndrome may stall, and the company also faces IP uncertainty, safety-signal risk, and competition from larger biopharma peers. Its pipeline adds little near-term comfort because key CNS programs, including ACP-204 in ADP and ACP-101 in hyperphagia in PWS, may fail or be delayed, with the remlifanserin trial already missing its primary endpoint at 60mg.
This aggregate rating is based on analysts' research of Acadia Pharmaceuticals Inc. and is not a guaranteed prediction by Public.com or investment advice.
ACAD Analyst Forecast & Price Prediction
Start investing in ACAD
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Acadia Pharmaceuticals Inc. (ACAD) Forecast
ACAD Analyst Forecast & Price Prediction
Start investing in ACAD
Order type
Buy in
Order amount
Est. shares
0 shares